$1.70 +0.04 (2.41%) Synthetic Biologics Inc - NYSE Amex Equities

Jul. 22, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 1.70
Trade Time: Jul 22 04:00 PM Eastern Daylight Time
Change: +0.04 (2.41%)
Prev Close: 1.66
Open: 1.67
Bid: 1.66
Ask: 1.73
  1. No results found.
  1. Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough (Pertussis)

    Benzinga | Oct. 21, 2015 | 07:00AM EST
  2. Synthetic Biologics' Novel IBS-C Program Featured in American College of Gastroenterology Poster

    Benzinga | Oct. 20, 2015 | 15:31PM EST
  3. Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial

    Benzinga | Sep. 28, 2015 | 06:57AM EST
  4. Synthetic Biologics Says First Analysis Shows SYN-004 Protects Microbiome from IV Antibiotics Damage in Humanized Pig Model

    Benzinga | Sep. 21, 2015 | 06:59AM EST
  5. Insiders Are Buying Freeport McMoRan and Phillips 66

    GuruFocus | Sep. 11, 2015 | 16:00PM EST
  6. Benzinga's M&A Chatter for Wednesday August 26, 2015

    Benzinga | Aug. 26, 2015 | 19:25PM EST
  7. Mid-Day Market Update: Monday's Movers, China's Trade, Oil And More

    Benzinga | Aug. 10, 2015 | 12:29PM EST
  8. Intrexon and Synthetic Biologics Enter ECC to Develop Novel Biotherapeutics for Treatment of Phenylketonuria

    Benzinga | Aug. 10, 2015 | 06:31AM EST
  9. Market Update: Thursday's Mid-Day Movers, Greece, Iran, IPOs And More

    Benzinga | Jul. 16, 2015 | 14:17PM EST
  10. Monday's Mid-Day Movers: Greece's Bank Shuts Down; Puerto Rico Unable To Pay Debts

    Benzinga | Jun. 29, 2015 | 13:28PM EST
  11. First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile

    Benzinga | Jun. 12, 2015 | 06:59AM EST
  12. Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infect

    Benzinga | Dec. 22, 2014 | 06:59AM EST
  13. Morning Market Movers

    Benzinga | Nov. 24, 2014 | 09:46AM EST
  14. Earnings Scheduled For November 14, 2014

    Benzinga | Nov. 14, 2014 | 05:05AM EST
  15. Synthetic Biologics Issues UCLA Report of Prelim. Positive Topline Efficacy, Safety Results from Phase II Study of Trimesta

    Benzinga | Apr. 29, 2014 | 15:46PM EST
Trading Center